Endocrinology and Metabolism

The Korean Endocrine Society (대한내분비학회)
권호 표지

Endocrine Disorders and Dyslipidemia

내분비질환과 이상지질혈증

Hong, Young-Sun
홍영선

  • Published : 2008.02.10
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Stone NJ: Secondary causes of hyperlipidemia. Med Clin North Am 78:117-141, 1994 https://doi.org/10.1016/S0025-7125(16)30179-1
  2. Chait A, Brunzell JD: Acquired hyperlipidemia (secondary dyslipoproteinemias): Endocrinol Metab Clin North Am 19:259-278, 1990
  3. Durrington PN: Secondary hyperlipidaemia. Br Med Bull 46:1005-1024, 1990 https://doi.org/10.1093/oxfordjournals.bmb.a072438
  4. Koppers LE, Palumbo PJ: Lipid disturbances in endocrine disorders. Med Clin North Am 56:1013-1020, 1972 https://doi.org/10.1016/S0025-7125(16)32366-5
  5. Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496-1504, 2004 https://doi.org/10.2337/diacare.27.6.1496
  6. Avramoglu RK, Basciano H, Adeli K: Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta 368:1-19, 2006 https://doi.org/10.1016/j.cca.2005.12.026
  7. Kolovou GD, Anagnostopoulou KK, Cokkinos DV: Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 81:358-366, 2005 https://doi.org/10.1136/pgmj.2004.025601
  8. Haffner SM: Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 90(suppl):55i-61i, 2002 https://doi.org/10.1016/S0002-9149(02)02634-6
  9. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD: Hepatic lipase and dyslipidemia: Interactions among genetic variants, obesity, gender, and diet. J Lipid Res 44:1279-1286, 2003 https://doi.org/10.1194/jlr.R200017-JLR200
  10. Hirona T: Lipoprotein abnormalities in diabetic nephropathy. Kidney Int 56, (suppl 71):S22-S24, 1999 https://doi.org/10.1046/j.1523-1755.1999.07106.x
  11. Shin DJ, Osborne TF: Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2(SREBP-2). J Biol Chem 278:34114-34118, 2003 https://doi.org/10.1074/jbc.M305417200
  12. Duntas LH: Thyroid disease and lipids. Thyroid 12:287-293, 2002 https://doi.org/10.1089/10507250252949405
  13. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V: Thyroid dysfunction and serum lipids: a community-based study. Clin Endocrinol 63:670-675, 2005 https://doi.org/10.1111/j.1365-2265.2005.02399.x
  14. Cappola AR, Ladenson PW: Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab 88:2438-2444, 2003 https://doi.org/10.1210/jc.2003-030398
  15. Pucci E, Chiovato L, Pinchera A: Thyroid and lipid metabolism. Int J Obes 24(suppl 2):S109-S112, 2000 https://doi.org/10.1038/sj/ijo/0801292
  16. Brenta G, Berg G, Arias P, Zago V, Schnitman M, Muzzio ML, Sinay I, Schreier L: Lipoprotein alterations, hepatic lipase activity and insulin sensitivity in subclinical hypothyroidism: response to L-T4 treatment. Thyroid 17:453-460, 2007 https://doi.org/10.1089/thy.2006.0302
  17. Grundy SM: Thyroid mimetic as an option for lowering low-density lipoprotein. Proc Natl Acad Sci U S A. 105:409-410, 2008
  18. De Boer H, Block GJ, Voerman HJ, Phillips M, Schouten JA: Serum lipid levels in growth hormonedeficient men. Metabolism 43:199-203, 1994 https://doi.org/10.1016/0026-0495(94)90245-3
  19. Kearney T, De Gallegos CN, Chrisoulidou A, Gray R, Bannister P, Venkatesan S, Johnston DG: Hypopituitarism is associated with triglyceride enrichment of very low-density lipoprotein. J Clin Endocrinol Metab 86:3900-3906, 2001 https://doi.org/10.1210/jc.86.8.3900
  20. Carroll PV, Christ ER, Bentsson BA, Carlsson I, Christiansen JS, Clemmons D, Hintz R, Ho KY, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorner MO: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 83:382-395, 1998 https://doi.org/10.1210/jc.83.2.382
  21. Beentjes JAM, Van Tol A, Sluiter W, Dullaart RPF: Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase activity and lipid transfer protein activities in growth hormone deficient adults. J Lipid Res 41:925-932, 2000
  22. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ: Serum lipoprotein changes following IGF-1 normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol 56:303-311, 2002 https://doi.org/10.1046/j.1365-2265.2002.01460.x
  23. Beentjes JAM, Van Tol A, Sluiter Wj, Dullaart RPF: Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis 153:491-498, 2000 https://doi.org/10.1016/S0021-9150(00)00433-0
  24. Rafnsson AT, Johannsson M, Olafsson I, Dallongeville J, Erfurth EM, Berg AL, Arnadottir M: Effects of different doses of adrenocorticotrophic hormone on the serum lipoprotein profile in healthy subjects. Basic Clin Pharmacol Toxicol 97:86-90, 2005 https://doi.org/10.1111/j.1742-7843.2005.pto_108.x
  25. Skoog M, Xu N, Berggren-Soderlund M, Lovegrove JA, Nilsson-Ehle P: ACTH reduces the rise in ApoB-48 levels after fat intake. Atherosclerosis 191:433-439, 2007 https://doi.org/10.1016/j.atherosclerosis.2006.05.012
  26. Johnston DG, Alberti KGMM, Nattrass M, Barnes AJ, Bloom SR, Jpolin GF: Hormonal and metabolic rhythms in Cushing's syndrome. Metabolism 29:1046-1052, 1980 https://doi.org/10.1016/0026-0495(80)90215-2
  27. Ottosson M, Vikman-Adolfsson K, Enerback S, Olivercrona G, Bjorntorp P: The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endrocrinol Metab 79:820-825, 1994 https://doi.org/10.1210/jc.79.3.820
  28. Arnaldi G, Mancini T, Polenta B, Boscaro M: Cardiovascular risk in Cushing's syndrome. Pituitary 7:253-256, 2004 https://doi.org/10.1007/s11102-005-1172-7
  29. Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R, Papadopoulos NM, Chrousos GP: Carbohydrate and lipid metabolism in endogenous hypercortisolism: Shared features with metabolic syndrome X and NIDDM. Endocrine J 43:645-655, 1996 https://doi.org/10.1507/endocrj.43.645
  30. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G: High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol 61:768-777, 2004 https://doi.org/10.1111/j.1365-2265.2004.02168.x
  31. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JMC: Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33:1364-1368, 1999 https://doi.org/10.1161/01.HYP.33.6.1364
  32. Bayrak A, Aldemir D, Bayrak T, Corakci A, Dursun P: The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Turkish postmenopausal women. Arch Gynecol Obstet 274:289-296, 2006 https://doi.org/10.1007/s00404-006-0187-2
  33. Godsland IF: Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 75:898-915, 2001 https://doi.org/10.1016/S0015-0282(01)01699-5
  34. Campos H, Walsh BW, Judge H, Sacks FM: Effect of estrogen on very low-density lipoprotein and low-density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab 82:3955-3963, 1997 https://doi.org/10.1210/jc.82.12.3955
  35. Van Pottelbergh I, Braeckman L, De Bacquer D, De Backer G, Kaufman JM: Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis 166:95-102, 2003 https://doi.org/10.1016/S0021-9150(02)00308-8
  36. Haffner SM, Mykkanen L, Valdez RA, Katz MS: Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 77:1610-1615, 1993 https://doi.org/10.1210/jc.77.6.1610
  37. Schleich F, Legros JJ: Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol 151:415-424, 2004 https://doi.org/10.1530/eje.0.1510415
  38. Legro RS, Kunselman AR, Dunaif A: Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 111:607-613, 2001 https://doi.org/10.1016/S0002-9343(01)00948-2
  39. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS: A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2007 Dec 4
  40. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP: Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 18:280-285, 2007 https://doi.org/10.1016/j.tem.2007.07.004
  41. Herrera E, Amusquivar E, Lopez-Soldado I, Ortega H: Maternal lipid metabolism and placental lipid transfer. Horm Res 65(Suppl 3):59-64, 2006 https://doi.org/10.1159/000091507